This paper purposes to evaluate the limits enforced by the Colombian legal system to
the derivative rights from the granting to invention patents in the pharmaceutical sector, in relation to the access to medical products. The evaluation analyses the applicable
rules to patent granting, patent protection, and the corresponding vigilance and control
duties. It then considers the stress concerning the right to the industrial property and
the right to health; it finally offers some recommendations that will help to regulate
the industrial property protection mechanisms and general interest, in relation to the
access to medicines.
